140+ supporters, real doctor founders, and breakthrough wound-care science.

4.8

5.0

recognized With Hundreds Reviews

Highest Rated Partner Dance School in Bay

based on Google Reviews

Most Historic Ballroom in Seattle

Proudly Recognized With Hundreds of Reviews

Invest in Heal Rapidly. Revolutionizing Faster, Pain-Free Healing

Step 1 of 4: Watch this video.

They Started Just Like You— Here’s How it’s Going

A patent-pending spray-on bandage engineered for faster healing, built by real doctors and backed by 140+ early supporters.

Step 2 of 4: Join the Investor List.

First Name *

Last Name *

Phone *

Email *

Why Should You Invest, and Why Now?

Heal Rapidly represents an extraordinary opportunity in the healthcare market, with a path to significant returns. By capturing just 4% of the market share of its closest competitor, it is our projection we aim to return your investment within three years. With the company’s current valuation at $3.5 million, a $400,000 investment translates to an 11.43% equity stake.

Thanks to a 50% margin on our product, we forecast $2.4 million in sales in the first two years, potentially yielding $1.2 million in net income. This would increase our company’s valuation to $6 million—a 5X return on net income. We expect sales to scale rapidly as the product gains market recognition and new claims are validated. We believe this funding round will be the final one needed to achieve our milestones.

Please note that these numbers are projections and are not guaranteed.

The Product: A Revolution in Wound Healing

Heal Rapidly is a patent-pending liquid bandage designed to transform wound care. This easy-to-use spray reduces pain, minimizes inflammation, and accelerates healing of cuts by 11 to 13 percent, based on promising results from controlled studies. In a burn wound study, a key result showed that by day four, wounds treated with Heal Rapidly were closing significantly faster than the control group. Specifically, we observed a 64.9 percent increase in wound closure in the treated wounds compared to the negative control, representing a statistically significant and clinically meaningful difference. In addition, recent agar well diffusion assays revealed potent antibacterial activity of the Heal Rapidly compound against both E. coli and Staphylococcus aureus. The zones of inhibition were highly significant with p less than 0.00001, highlighting Heal Rapidly’s strong potential to combat bacterial pathogens. We are seeking 400,000 dollars in this final funding round to secure FDA approval as a liquid wound dressing and bring Heal Rapidly to market within six months.

The Problem: Gaps in Current Wound Care Solutions

Wound care has remained largely unchanged for decades. Most treatments offer minimal comfort, and if infection or debris is present, healing time increases significantly. Existing products are often messy, have unpleasant odors, and may cause pain or even mild toxicity. Furthermore, most lack reliable evidence of efficacy, leaving consumers frustrated and underserved.

Our Solution: Heal Rapidly

Heal Rapidly is a game-changing solution. This simple spray not only reduces pain but also creates an optimal moist environment for faster healing. By promoting a healthier, infection-free healing process, it accelerates recovery while providing comfort. Heal Rapidly is scientifically designed to reduce inflammation, protect against infection, and enhance healing speed, offering a unique and much-needed alternative to current options.

Market Opportunity: Capturing a Growing Market

Heal Rapidly enters a market dominated by products that fail to address the critical needs of faster healing and pain relief. Our closest competitor is a stabilized hypochlorous acid solution approved by the FDA as a topical wound dressing. While it sold 70,000 units on Amazon at $30 for a 3 oz spray in August 2023, it lacks evidence of accelerated healing or pain relief. Heal Rapidly outshines this product with proven efficacy and a competitive price of $20 for a 2 oz spray.

Additionally, common alternatives such as silver compounds, antibiotic ointments like Neosporin, and debridement agents like iodine and peroxide do not accelerate healing or reduce pain. Heal Rapidly fills this gap with a product backed by science, positioned to disrupt a multi-million-dollar industry.

Potential for Future Expansion of Claims

Beyond its current applications, Heal Rapidly shows immense potential for expansion into additional therapeutic areas. Anecdotal evidence and early-stage trials suggest that Heal Rapidly may be effective in treating a variety of conditions, including:

Burns, Cuts, and Abrasions: Accelerates healing and reduces pain from minor burns, cuts, and abrasions.

Sunburns: Quickly alleviates pain by reducing inflammation and accelerating the healing process, providing fast relief and comfort.

Insect Bites: Effective for bites from spiders, yellow jackets, wasps, mosquitoes, and other insects.

Marine and Environmental Injuries: Provides relief from injuries caused by coral, and stinging jellyfish.

Skin Infections: Demonstrated efficacy in treating infections such as MRSA (Methicillin-resistant Staphylococcus aureus).

Mouth Sores: Alleviates pain from aphthous stomatitis (mouth ulcers).

Veterinary Use: Shown to relieve skin irritation in pets, including cats and dogs.

These promising uses position Heal Rapidly to expand its product claims, offering both short-term growth and long-term diversification potential.

The Ask: Join Us in Transforming Wound Care

Your investment in Heal Rapidly will enable us to complete the FDA approval process and bring this innovative product to market. With proven safety and efficacy, a clear path to growth, and the potential to revolutionize wound care, Heal Rapidly offers an exceptional opportunity for both financial returns and meaningful impact in healthcare.

Team

Inventors

Jack Konowalchuk, PhD (deceased) - world-famous virologist who was the first to discover a test for E. coli endotoxin
Thomas Konowalchuk, MD, JD - manager of Heal Rapidly, LLC

Consultants

Gitali Indra, PhD - research scientist at Oregon State University, College of Pharmacy
Arup Indra PhD - research scientist at Oregon State University, College of Pharmacy
All Pro Webworks, LLC - website support
RQM+ - regulatory consulting firm
Cristina Mejía - Chief of Communications.

GLP manufacturing and bottling company

Yellow Emperor

Sales distribution and returns company

Amazon

Members of our professional/advisory support team

Attorney: Travis Young of Bozicevic, Field & Francis LLP
Accountant: Rashellee Herrera CPA, CISA, CIA, CFE, cCAE of RNB Capital, LLC

Advisory board

Kasten Spethmann - Capital Access Team Advisor

Competitive Landscape: A Unique Market Opportunity

Heal Rapidly is poised to create a distinct and profitable segment within the wound care market. Currently, no product exists that accelerates wound healing safely and effectively, as proven in clinical studies. Consumers are increasingly looking for solutions that allow them to heal quickly and comfortably without fear of adverse reactions. Heal Rapidly addresses this gap by offering a clinically validated solution that accelerates healing, reduces pain, and provides protection against infection.

We will position Heal Rapidly as the breakthrough treatment that the market has long awaited a product, that not only meets the needs of consumers but also offers a unique, science-backed solution that will transform wound care.

Business Mechanics: A Clear Path to Profitability

Our financial model is designed with one primary goal in mind: to repay your investment within three years and then distribute the majority of profits to our investors. Based on the current revenue model, the company is projected to reach a net value of $6 million within two years of sales. This valuation is grounded in the successful FDA approval of Heal Rapidly and two years of online sales, generating an estimated $2.4 million in gross revenue.

With a 50% profit margin, the $2.4 million in sales will translate into $1.2 million in net income, which drives the company’s valuation to $6 million (a 5X multiple on net income) by year three. The projected five-year income model reflects a slight dip below 50% net profit due to initial ramp-up costs, but we anticipate rapid growth once the product is launched.

The first year will involve no sales during the initial 9-month period while fundraising efforts and FDA approval are underway, followed by a strong sales ramp-up once Heal Rapidly enters the marketplace.

Finances: Strong Financial Growth and Global Expansion Potential

Heal Rapidly is currently patent-pending in the United States, with 20 years of patent protection, providing a solid foundation for long-term market dominance. We plan to file additional patents in other countries during the first year of operations to expand our global footprint.

The pre-money valuation of the company is estimated at $3.5 million, based on the initial market for minor human trauma treatment in the United States. However, the financial potential extends far beyond this initial market. Heal Rapidly has promising applications for other common human conditions, such as:

- Burns

- Insect Bites

- Simple Diabetic Ulcers

- Inflammation

Additionally, Heal Rapidly can be used in veterinary care to treat conditions such as allergic itching and other skin ailments in animals.

As consumer awareness and acceptance grow in these additional markets, Heal Rapidly’s valuation is expected to significantly increase, offering investors an opportunity for substantial returns as the product expands into new therapeutic areas.

Let's change how the world heals.

Investing is risky. You could lose all your money. Only invest what you can afford to lose. Most investments are hard to sell, and there’s no promise you’ll get your money back or make a profit. Wefunder does not offer investment advice. Do your own research. Content is provided by the company. Wefunder does not fact-check every statement.